Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Michael Dustin of the Kennedy Institute of Rheumatology comments on new research into boosting the immune system's response to cancer with cholesterol, in Nature

The ability to stimulate our immune system in the fight against cancer or autoimmune diseases is now a reality, but there are still challenges to overcome and further medical advances to pursue.

With 50% of people born after 1960 set to be diagnosed with some form of cancer during their lifetime, developing successful treatments is a key focus of biomedical research.

 

This work may give a new meaning to "good" cholesterol.
- Professor Michael Dustin

New research also published in Nature proposes a way to boost the function of anti-tumour T cells, using a metabolic trick to increase the level of cholesterol in the cells' membranes, bringing new hope to patients worldwide.

T cells determine the specificity of our immune response to foreign substances in the body, like tumour cells. They sense these substances through clusters of T-cell receptor proteins on a cell's surface, which then initiate T cell activation. This activation can be enhanced by a number of factors or substances, namely cholesterol on the cell membrane.

The research team has used a drug to stop cholesterol being converted into cholesterol ester, which led to higher cholesterol levels in the cell membrane of killer T cells, promoting clustering of T-cell receptors that bind to the surface of tumour cells. Higher-membrane cholesterol also led to an increase in the speed at which the T cell and tumour cell form a point of embrace called the immunological synapse, a crucial step in our immune response. Together, these factors promoted the release of molecules that trigger tumour-cell death.

"This work may give a new meaning to "good" cholesterol. The potential to combine this approach with an established immunotherapy like anti-PD-1 is exciting as drug combinations offer advantages for targeting heterogeneous or rapidly mutating disease agents- like cancer and viruses", 

Professor Dustin 's research at the Kennedy focuses on immunological synapse (IS), a term he first coined to describe the embrace between T cells and B cells that is necessary to mount an immune response. His current work aims to improve vaccines and immunotherapy by revealing the composition of particular structures related to immunological synapses, defined as synaptic ectosomes, as well as identify ways to manipulate their formation.

 

Image copyright: Nature.

NATURE | NEWS & VIEWS
Cancer immunotherapy: Killers on sterols

Associated article
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
by Yang et al.

 

The immunological synapse explained

 

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Drug may boost vaccine responses in older adults

General Research

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

3D imaging reveals the role of blood vessels in hormone production

Research

New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.

Wellcome funding awarded to Oxford team to support research into heart muscle regeneration

Awards Research

An Oxford team from the Centre for Medicines Development, Department of Physiology Anatomy and Genetics and Radcliffe Department of Medicine led by Professor Jagdeep Nanchahal at the Kennedy Institute has been awarded a Wellcome Innovator Award to develop a first in class therapeutic aimed at regenerating heart muscle after heart attack.